



Published in final edited form as:

ACS Infect Dis. 2020 July 10; 6(7): 1587–1598. doi:10.1021/acsinfecdis.9b00515.

Small molecule sensors targeting the bacterial cell wall

Matthew F. L. Parker¹, Robert R. Flavell¹, Justin Luu¹, Oren S. Rosenberg^{2,*}, Michael A. Ohliger^{1,3,*}, David M. Wilson^{1,*}

¹Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94158, USA


²Department of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA

³Department of Radiology, Zuckerberg San Francisco General Hospital, San Francisco, CA 94110, USA

Abstract

This review highlights recent efforts to detect bacteria, using engineered small molecules that are processed and incorporated similarly to their natural counterparts. There are both scientific and clinical justifications for these endeavors. The use of detectable, cell-wall targeted chemical probes has elucidated microbial behavior, with several fluorescent labeling methods in widespread laboratory use. Furthermore, many existing efforts including ours, focus on developing new imaging tools to study infection in clinical practice. The bacterial cell wall, a remarkably rich and complex structure, is an outstanding target for bacteria-specific detection. Several cell wall components are found in bacteria but not mammals, especially peptidoglycan, lipopolysaccharide, and teichoic acids. As this review highlights, the development of laboratory tools for fluorescence microscopy has vastly outstripped related positron emission tomography (PET) or single photon emission computed tomography (SPECT) radiotracer development. However, there is great synergy between these chemical strategies which both employ mimicry of endogenous substrates to incorporate detectable structures. As the field of bacteria-specific imaging grows, it will be important to understand the mechanisms involved in microbial incorporation of radionuclides. Additionally, we will highlight the clinical challenges motivating this imaging effort.

Graphical Abstract



*Correspondence and Reprint Request: David Wilson, M.D., Ph.D., Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave., San Francisco, CA 94143, USA, Phone: (415) 353-1668, Fax: (415) 353-8593, david.m.wilson@ucsf.edu, Michael Ohliger, M.D., Ph.D., Department of Radiology and Biomedical Imaging, University of California, San Francisco, 1001 Potrero Ave., San Francisco, CA 94110, USA, Phone: (415) 206-8024, Fax: (415) 206-4004, michael.ohliger@ucsf.edu, Oren Rosenberg, M.D., Ph.D., Department of Medicine, University of California, San Francisco, 513 Parnassus Ave., San Francisco, CA 94143, USA, Phone: (415) 514-0412, Fax: (415) 476-9364, oren.rosenberg@ucsf.edu.

Keywords

infection; imaging; peptidoglycan; nuclear medicine; chemical biology

A. Introduction and scope of review:

The last decade has showed remarkable progress in detecting and characterizing bacterial pathogens non-invasively. Cell-wall derived techniques abound in this area, are both driving our understanding of microbial behavior and inviting new human-compatible imaging technologies. In this review, we will focus on the bacteria-specific structures found in or proximal to the cell wall, including transporter proteins and membrane-bound components such as penicillin-binding proteins. In particular, we will discuss elements targeted for fluorescent probe and positron emission tomography (PET) and single photon enhanced computed tomography (SPECT) tracer development, with an emphasis on clinically relevant approaches and discoveries. This review will generally be limited to non-mycobacterial structures and components seen in multiple species of gram-positive and gram-negative pathogens.

We will begin by highlighting the clinical challenges motivating this imaging effort, and follow with a discussion addressing fluorescent versus PET/SPECT detection methods, with the latter focused on imaging human-relevant pathogens via tomographic techniques. In general, fluorescent tools that study bacteria and their behavior *in vitro* are much more highly evolved in the literature, with numerous elegant studies highlighting the incorporation of fluorescent D-amino acid analogues and other cell-wall specific structures. The review will then describe direct versus pre-targeted detection strategies. Steric effects frequently justify the incorporation of “clickable” moieties into bacterial structures, which can be subsequently detected via bio-orthogonal reactions with frequently bulky and structurally complex fluorescent probes. Finally, we will illustrate several small-molecules targeting cell wall structures that either bind cell-wall related proteins, or are metabolic precursors for the cell wall itself. This discussion will enumerate the basic differences between gram-negative and gram-positive cells which could potentially allow distinguishing between the two in key disease contexts. As the structural features of the bacterial cell wall are detailed, we will see that several components are likely bacteria-specific, whereas others are frequently found in fungi, mammals, and other organisms.

B. Clinical justifications:

Imaging studies are frequently used in the evaluation of infected patients, particularly important in identifying the presence and location of infection, and documenting response to antimicrobial therapy. These imaging approaches generally rely on structural changes, detecting abnormal tissue edema or fluid by standard radiography, computed tomography (CT), and magnetic resonance (MR). In contrast, the nuclear imaging techniques positron emission tomography (PET) and single photon emission computed tomography (SPECT) add biochemical and functional information. Current clinical methods include 2-deoxy-2-[¹⁸F]fluoro-D-glucose([¹⁸F]FDG)-PET, the [¹¹¹In]WBC scan, and gallium-derived

tools (^{67}Ga and ^{68}Ga for SPECT and PET respectively)¹⁻⁶. The mechanisms of these tracers are beyond the scope of this review, but they generally image the host immune response to active infection rather than the bacteria themselves. Therefore, these tools may fail to differentiate active infection from sterile inflammation.

In response to this limitation, newer radiotracers have targeted bacteria-specific metabolism, by exploiting basic differences between mammalian and bacterial cells. For example, sorbitol-derived radiotracers are highly sensitive to Enterobacteriaceae but not mammalian cells⁷, while para-aminobenzoic acid (PABA)^{8,9} and trimethoprim-derived probes¹⁰ can detect the bacterial folate generating pathway. These and related approaches are expected to have an expanding clinical role in the next decade. Cell-wall and membrane-targeted agents also hold special promise, complementing the detection of cytoplasmic and nuclear targets. Targeted structures include both structural constituents of the cell wall (peptidoglycan, teichoic acids, LPS), and relevant cell-wall and membrane proteins especially transporters. The use of all pathogen-targeted imaging methods is somewhat complicated by the normal human microbiome¹¹. However, the microbiome is generally well-sampled, easily accessible via the skin and aerodigestive tract. Many analytic tools investigating the microbiome are *ex vivo*, for example using the stool and/or biofluids such as sputum¹²⁻¹⁴. Therefore the described imaging methods are most helpful in settings where these traditional sampling methods fail. In particular, rapid methods to diagnose bacterial infection will be most helpful for triaging acutely ill patients. Depending on the radiotracers used, imaging studies can reveal (1) the location of infection (2) the type of organism i.e. gram-negative versus gram-positive (3) response to antimicrobial therapy and (4) the presence of resistant pathogens. We believe that new imaging tools are essential in the following clinical scenarios:

1. Infection of deeper, normally sterile spaces:

Successful diagnosis of infection involving the intervertebral discs and other joint spaces (hips, knee, etc.) is frequently difficult in clinical practice, even using magnetic resonance imaging (MRI). Percutaneous sampling of these spaces is frequently needed which can be insensitive, costly and potentially dangerous for the patient. For example, vertebral discitis-osteomyelitis represents a major diagnostic challenge even when advanced imaging is employed, highlighted in several reports^{15,16}. Another example of a sterile region that is not easily accessed is the biliary tract and pancreas. It can be difficult to diagnose cholangitis (infection of the biliary system)¹⁷ and infected pancreatitis which may occur in the context of pancreatic pseudocysts¹⁸. The pancreas and biliary system are not easily sampled, and diagnostic tools compatible with full-body cross-sectional imaging are needed.

2. Infection that occurs in the presence of inflammatory mimics:

For several entities, imaging and other diagnostic studies cannot separate acute infection from sterile inflammation. This distinction is of critical importance for treatment, since opposite treatments are frequently used for these two entities. A patient who has an acute bacterial joint infection requires urgent antibiotic therapy, while the inflammation associated with rheumatoid arthritis or gout is treated with nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Other critical infections include those of the diabetic foot¹⁹, or *P. aeruginosa* pneumonias in cystic fibrosis patients²⁰.

3. Infection in patients who cannot mount an immune response:

As discussed above, most nuclear medicine tools used in clinical practice image the host response to infection rather than the bacteria themselves. Both [^{18}F]FDG and [^{111}In]WBC scans identify immune cells trafficked to the area, while gallium-derived radiotracers sense transferrin²¹ which is upregulated in the acute phase of infection²². A large number of patients cannot mount an immune response, especially seen in human immunodeficiency virus (HIV), blood/bone marrow cancers, hereditary diseases and drug-related disorders. Frequently these patients can be afebrile, and have a normal or low white blood-cell count. Accurate methods to detect living bacteria would be critical in this population.

C. Fluorescence- the origin of nuclear imaging tools:

As highlighted by this review, many of the newer imaging methods (i.e. PET and SPECT) targeting the cell wall have been motivated by related fluorescence-based techniques. Fluorescent molecules have largely been studied *in vitro* and have contributed significantly to our understanding of bacterial behavior especially cell-wall remodeling. The advantages and disadvantages of fluorescent detection are highlighted in Table 1, with the clear benefits being (1) lower cost (2) diversity of chemical structures employed and (3) activatable or “tunable” signals. In contrast, PET and SPECT hold major advantages for *in vivo* imaging, with both techniques compatible with clinical translation. In contrast to fluorescence-based methods, which have a limited depth of penetration into tissues, PET and SPECT have been used in humans for decades to assess the metabolic activity of deeper, non-accessible human organs including the brain^{23–25}. PET is highly sensitive, with the obtained spatial resolution benefitting from modern time-of-flight scanners²⁶. Most academic centers in the United States have adopted PET as their primary nuclear imaging tool, based on both this high sensitivity and ease of radionuclide incorporation into small-molecules structures of interest including metabolites. This is particularly true for ^{11}C and ^{18}F radionuclides for which substitution likely induces fewer perturbations of biologic behavior. For ^{11}C metabolites, structures can be generated that are chemically identical to those of their parent molecules²⁷. This strategy is also a key feature of the most commonly used PET radiotracer [^{18}F]FDG, which is a substrate for both glucose transporters (GLUTs) and hexokinase. Many radionuclides have been used to image infection, including ^{11}C (PET, $t_{1/2}$ = 20 min), ^{68}Ga (PET, $t_{1/2}$ = 68 min), ^{18}F (PET, $t_{1/2}$ = 110 min), $^{99\text{m}}\text{Tc}$ (SPECT, $t_{1/2}$ = 6 h), ^{64}Cu (PET, $t_{1/2}$ = 13 h), ^{111}In (SPECT, $t_{1/2}$ = 67 h), ^{201}Tl ($t_{1/2}$ = 73 h), ^{67}Ga (SPECT, $t_{1/2}$ = 78 h), ^{89}Zr (PET, $t_{1/2}$ = 78 h), ^{124}I (PET, $t_{1/2}$ = 4.2 d).

With respect to the bacterial cell wall, several recent studies have demonstrated the synergy of optical and nuclear imaging. Work published by Ning et al. from the Murthy group using maltohexose derivatives highlights the scope and limitations of both approaches for *in vivo* imaging. Figure 1 depicts both NIR-dye modified²⁸ and ^{18}F labeled²⁹ maltohexose derivatives, both synthesized using click chemistry. Similarly, there is a rich history in the fluorescence literature describing the use of D-amino acid derived probes targeting the bacterial cell wall. Figure 2A shows the structures of two D-amino acid derived structures that use 7-hydroxycoumarin 3-carboxylic acid and 4-chloro-7-nitrobenzofuran to make HADA and NADA respectively, fluorescent sensors used for *in vitro* analysis³⁰. In contrast

Figure 2B depicts D-amino acid derived structures for PET namely D-[methyl- ^{11}C]methionine (D- ^{11}C met) and D-[3- ^{11}C]alanine (D- ^{11}C ala)^{31–33} which were used both *in vitro* and *in vivo* to study pathogenic bacteria. The radiosynthesis of D- ^{11}C ala from a glycine precursor using a cinchonidinium-derived chiral catalyst is depicted in Figure 2C.

D. Direct versus “clickable” detection technologies:

Especially with respect to fluorescent D-amino acids (FDAAs), bacterial structures have shown marked promiscuity in incorporating fluorophore-modified small molecules. However, any significant deviations from canonical structures (i.e. D-alanine and D-glutamate) impart changes to biochemical behavior based on size, lipophilicity, and solvation properties³⁴. Figure 3 shows the dramatic relationship between FDAA side-chain and bacterial accumulation with smaller linkers seemingly favored. Numerous tools for chemical biology have been developed to address this issue, by incorporating structures capable of detection into biologic systems. If visualization of FDAAs via mucopeptide incorporation in the periplasm is considered “direct,” an indirect approach would be the incorporation of a chemically and biochemically inert D-amino acid into peptidoglycan, that is identified later via reaction with a second, fluorescent chemical moiety. This may be accomplished via a “bio-orthogonal” or “click” reaction whereby the two components are reactive with each-other, but otherwise stable in the biologic milieu³⁵. The first methods used for click-chemistry dependent D-amino acid visualization³⁶ is described in Figure 4A, while more advances in click chemistry are highlighted in Figures 4B/C including nitrene-based cycloaddition chemistry, where strained cyclooctyne-bearing fluorophores are reacted with nitrene derivatives of alanine and lysine and the corresponding adducts studied for bacterial incorporation³⁷. In addition to the previously described steric advantages of using less bulky metabolites in biologic systems, another major consideration is pre-targeting. In other words, the modified cell-wall metabolite could be introduced into a biologic system over time if needed, with subsequent observation more dependent on the pharmacokinetics and reactivity of the fluorescent label. This mechanism of bacterial detection has been explored beyond D-amino acid utilization, with similar methods used to image N-acetyl muramic acid and KDO incorporation via generating a fluorescent product³⁸. These cell-wall components are described more precisely later in the review. To our knowledge, a clickable, pre-targeted approach has not been described to image bacteria-specific structures using SPECT or PET. This is true despite the heavy use of bio-orthogonal methods to image antibodies and other biomolecules in nuclear imaging^{39–42}. For *in vivo* imaging, click approaches need to overcome significant technical hurdles including addressing the use of copper for many reported *in vitro* methods⁴³.

E. Targeting proteins proximal to the cell wall:

The first class of molecules we will consider are cell-wall specific proteins especially peptidoglycan-remodeling enzymes and bacterial-metabolite specific transporters. The most established approach to imaging cell-wall proteins is *via* modified antibiotic structures, with several recent *in vivo* methods targeting bacterial transport.

1. Antibiotic targets: fluorescent and radiolabeled sensors:

There is extensive literature regarding antibiotics, and their corresponding cell-wall protein targets as bacteria-specific imaging probes. Of note, antibiotics targeting the cell wall are not intrinsically fluorescent (as is the case for DNA-targeted antibiotics mithramycin, chlromamycin A3, and olivomycin), and thus conjugation to a fluorophore is required. Specifically, cell wall-targeted antibiotics that have been conjugated with fluorophores include β -lactams, vancomycin, ramoplanin, and polymyxin B⁴⁴⁻⁴⁷ meeting varying degrees of success in bacterial detection. Figure 5 contrasts two vancomycin-derived compounds that have been conjugated for visualization via SPECT and fluorescence^{45,48,49}. Fluorescent conjugates have been used for imaging especially using NIR fluorophores⁵⁰, but importantly they also may be turned “on” or “off” during binding, metabolism, and response to the microenvironment. Therefore these probes have been used to study antimicrobial resistance, mode of action, and toxicity; for an outstanding review see Stone *et al.* 2018⁴⁹. An important limitation in developing related PET and SPECT tracers is that much of this information is potentially lost in using a radionuclide that is always “on.” Other important limitations of imaging radiolabeled antibiotics via SPECT and PET are the signal depends on probe-protein affinity and the concentration of the target which may not be sufficient and there is no turnover benefit, i.e. the maximum signal is stoichiometric. These considerations suggest that imaging probes metabolized and incorporated by living, intact bacterial machinery have a significant advantage. Historically the most successful imaging probes are those that undergo biotransformation and incorporation for example FDG⁵¹, although this thinking is challenged by the dramatic successes of affinity-based imaging methods for example those targeting PSMA in humans⁵². Regardless, antibiotic-derived PET and SPECT tracers have historically shown limited *in vivo* success detecting bacterial infection^{53,54}, although more recently reported trimethoprim analogues have shown outstanding data in preclinical models¹⁰. In other cases, labeled antimicrobial agents can be used to help us better understand therapeutic resistance, as is the case for [¹¹C]rifampin⁵⁵.

2. Bacteria-specific metabolite transporters:

In the last decade, there has been a pronounced interest in imaging pathogens using bacteria-specific metabolic pathways. This is best accomplished using PET probes that are metabolized and incorporated by bacteria but not their mammalian hosts. Published approaches include radiolabeled versions of para-amino benzoic acid (PABA)^{8,9}, trimethoprim¹⁰, sorbitol^{7,56,57}, maltose/maltotriose/maltohexose^{29,58-60}, arabinofuranoses⁶¹, and bacterial siderophores⁶². These technologies in particular the sorbitol-derived radiotracer 2-deoxy-2-[¹⁸F]fluorosorbitol ([¹⁸F]FDS) have recently been applied to patients suffering from bacterial infection. There are outstanding reviews of this emerging field published elsewhere⁶³⁻⁶⁵, but an important consideration is that these approaches likely rely heavily on bacteria-specific transport. The transporter used by [¹⁸F]FDS was incompletely characterized by Weinstein *et al.*, but they did note that [¹⁸F]FDS uptake was outcompeted by concentrations of sorbitol above 40 mg/ mL⁷. As indicated above, several probes have also targeted the maltose-maltodextrin transport system⁶⁶. For [¹⁸F]FDG, active transport of the probe (*via* GLUT 1,3,4) is very important and difficult to saturate. At our institution we determined that the concentration of glucose present in a patient-administered [¹⁸F]FDG

sample was approximately 1 mM, reinforcing the need for a high transporter K_m if competing unlabeled metabolites are present⁶⁷.

F. Structure of gram-negative and gram-positive cell walls:

The basic differences between gram-negative and gram-positive bacteria are essential to consider in developing cell-wall targeted metabolic probes. The basic membrane structures are highlighted in Figure 6A, which shows the relative contribution of peptidoglycan, the strong and elastic polymer that both protects bacteria from attack, and contributes to cell-cell signaling and quorum sensing^{68,69}. Of course it is the peptidoglycan component that renders bacteria gram-negative versus gram-positive, with the latter organisms better identified by Gram staining due to the higher concentration of peptidoglycan (90% by dry-weight versus 10% in gram-negatives). The basic structure of the peptidoglycan monomer is shown in Figure 6B indicating the sugar-derived components N-acetyl glucosamine and N-acetyl muramic acid as well as the muramic acid pentapeptide. Extensive data has shown that both pathogen classes can be detected using D-amino acid derived sensors, which may be of value *in vivo* in documenting the presence of infection versus other diseases^{32,33}. However, for antibiotic selection in the acute setting, determining the presence of gram-negative *or* gram-positive pathogens would also be of high value. Therefore, structures found only in gram-negative or gram-positive organisms are of high interest. In gram-negatives these include lipopolysaccharide (LPS), which is composed of a lipid and polysaccharide composed of O-antigen, outer core and inner core, found in the outer membrane.⁵⁹⁻⁶¹ In gram-positives, cell-wall teichoic acids are used. As discussed subsequently many of these components have been targeted by fluorescence methods and other detection methods.⁶²⁻⁶⁸

G. Cell wall component-derived sensors:

Our group and others are particularly enthusiastic about small molecules that are readily incorporated into the bacterial cell wall, with structural modifications that allow subsequent detection. This is in contrast to previously described sensors that interface with membrane proteins, for example penicillin-binding proteins and sugar transporters. The data on D-amino acids is particularly robust, having been used by both fluorescence and PET to characterize living bacteria. Another peptidoglycan constituent is N-acetyl muramic acid which has been modified for bacterial detection *via* a bio-orthogonal approach. We will also briefly summarize gram-negative and gram-positive specific structures that have been targeted for imaging especially LPS.

1. Peptidoglycan:

Not surprisingly, peptidoglycan has been investigated extensively as a way of detecting bacteria and differentiating them from mammalian cells. This is certainly true pathologically where Gram staining can identify peptidoglycan-rich bacteria such as *S. aureus* as well as identify their typical morphology. Numerous antibiotics are based on inhibition of peptidoglycan-processing enzymes, for example the penicillins, cephalosporins, and vancomycin⁷⁰⁻⁷². More recently, microbe detection has become a critical focus for developing new chemistries. Many of these have employed D-amino acids which are incorporated into peptidoglycan via distinct pathways. Literature supports an intracellular,

racemase-dependent assimilation of the canonical D-amino acids D-alanine and D-glutamine^{73,74}, but a more permissive “swapping” of muropeptide DAAs in the periplasm whereby D-alanine can be substituted for an introduced substrate⁷⁵. This mechanism has been used extensively by FDAAs in recent literature, via either direct incorporation of a FDaA or use of a bio-orthogonal DAA/ fluorescent detector pair. One exciting feature of fluorescence-based methods is the potential to build a full palette of frequency-specific molecules⁷⁶.

More recently the use of DAA-derived sensors for PET has been explored, using ¹¹C-labeled DAAs whose chemical structures match those of endogenous peptidoglycan substrates^{31,32}. Numerous data have shown that while exogenous D-alanine and D-glutamine show the most avid incorporation into bacteria, other DAA show significant accumulation^{75,77}. Since this is true for D-methionine, a radiosynthesis of D-[¹¹C]met was developed, that showed accumulation of signal in living bacteria but not heat-killed inoculation³¹. This study set the stage for developing the more synthetically challenging DAA substrates like D-[¹¹C]ala that show an order of magnitude enhancement of sensitivity to bacteria³³. One limitation that has been inadequately addressed is the metabolic fate of D-amino acid derived structures in mammals. For example, mammals may convert D-amino acids to their corresponding L-amino acids via the activity of D-amino acid racemases⁷⁸ or to their corresponding α -keto acids via D-amino acid oxidases⁷⁹. For example, D-alanine itself can be converted to pyruvate, with rapid subsequent metabolism in bacteria and mammalian tissues. Developing D-amino acid sensors that are resistant to these and other host metabolic pathways represents a critical component of imaging probe development.

While D-amino acid-derived probes target peptidoglycan muropeptides, another approach to detecting the cell wall uses bacteria-specific sugars especially muramic acid and N-acetyl muramic acid. The sugar backbone of peptidoglycan is composed of this amine sugar as well as N-acetyl glucosamine making a repeating “NAM-NAG” structure. A recently published method uses a modified N-acetyl muramic acid that is incorporated into peptidoglycan, and subsequently detected using a bio-orthogonal reaction⁸⁰ as highlighted in Figure 7. In contrast N-acetyl glucosamine is a substrate for bacterial, mammalian, and fungal metabolism and thus derived imaging methods derived from this structure would likely lack the desired bacterial specificity. In fungi, N-acetyl glucosamine molecules connected via β -(1,4) linkages form chitin, a primary component of the cell wall.⁸¹ In humans, N-acetyl glucosamine is used as a treatment for osteoarthritis and inflammatory bowel disease (IBD) including Crohn’s disease and ulcerative colitis.⁸² The first *in vivo* study using N-[¹⁸F]fluoroacetyl-D-glucosamine targeted tumors, based on the hypothesis that the hyaluronic acid concentration is a tumor biomarker.⁸³ A more recent study developed a new radiosynthesis of this compound, that was used to image *E. coli* infection in rats.⁸⁴ Although, N-[¹⁸F]fluoroacetyl-D-glucosamine demonstrated selectivity to live bacterial infection in comparison to sterile inflammation, FDG still outperformed this probe with 3-fold greater accumulation in the targeted region.

2. Gram-negative specific components:

The marked uptake of [^{18}F]FDS in Enterobacteriaceae relative to gram-positive bacteria highlights the possibility of specifically imaging this class of bacteria.⁷ The accumulation of [^{18}F]FDS appears to be transporter and kinase dependent, but there are also structural constituents of the gram-negative cell wall that might be targeted for specific detection of this class. For example, a major component of the outer membrane of bacteria are lipopolysaccharides (LPS) also known as “endotoxin.”⁸⁵ LPS is composed of three structural components. O-antigen, the outermost polysaccharide domain. The core domain, containing the sugar 3-deoxy-D-manno-oct-2-ulosonic acid (KDO). Lipid A is a phosphorylated glucosamine disaccharide connected to several fatty acids. In the last several years, a chemical strategy of *in vitro* sensing LPS has been reported and used based on the bacteria-specific KDO structure^{38,86,87}. As highlighted in Figure 8, this labeling technique uses an azide-modified analogue of 3-deoxy-D-manno-octulosonic acid. Click chemistry can subsequently be used to detect metabolic incorporation of this moiety.

3. Gram-positive specific components:

As previously discussed, strategies targeting peptidoglycan should inherently produce higher signal in gram-positive organisms, although recent PET experiments highlight that this is not always the case³². Teichoic acids are polymers of sugar alcohols (ribitol, glycerol) linked to carbohydrates via phosphodiester bonds⁸⁸. They are found within the cell wall of several important gram-positive pathogens including the genera *Staphylococcus* and *Streptococcus*. Teichoic acids can be either tethered to components of peptidoglycan more superficially (in particular D-alanine and muramic acid) or anchored to the lipid membrane and referred to as lipoteichoic acids (LTA's). Several components involved in the biosynthesis of teichoic acids are the “Tar” enzymes: TarA, TarB, TarF, TarK, TarL, TarO.⁸⁹ Understanding the roles and expressions of these enzymes would be crucial in targeting teichoic acid components for gram-positive detection via a chemical biology approach, which to our knowledge has not been reported. Recent papers have described fluorescence microscopy and force microscopy imaging of cell wall teichoic acids, concluding that the distribution of wall teichoic acids affects cell morphology, elongation, and division.⁹⁰ In addition, an antibody-based imaging method has been explored to detect gram-positive organisms. Specifically, an ^{89}Zr -labeled antibody (anti-LTA mAb) specific for LTA (^{89}Zr]SAC55) was synthesized, that exhibited specific binding *in vitro* (2 fold increase over background) to LTA-expressing bacteria.⁹¹ The potential of this method was highlighted via *in vivo* studies that showed statistically significant distinction of infection over sterile implant sites. Finally, a series of structures have been reported that are sensitive to the glycoprotein structure of the gram-positive cell surface, but whose precise mechanism of detection has not been elucidated. These include boronic acid-containing probes for example the recent BODIPY derivative BacGO⁹², hexidium⁹³, and wheat-germ agglutinin⁹⁴.

H. Species-specific cell wall structures:

Detecting a single species can frequently be of high clinical interest, especially in a suspected case of tuberculosis. Imaging specific to *M. tuberculosis* would be very important because this disease is so difficult to diagnose and treat. The complex cell wall of

mycobacteria⁹⁵ contains numerous possibilities to sense this bacteria. For example, several reports have described sensing trehalose glycolipids, with related strategies explored for fluorescence and nuclear imaging^{96,97}. Other examples of potentially species-specific structures are siderophores and their associated membrane receptors^{98,99}.

I. Conclusions:

Sensors of bacterial cell wall components have taken a central role in elucidating microbial behavior, and are expected to impact diagnostic imaging tools in the near future. As highlighted in this review, there is tremendous synergy between fluorescence-based tools that are primarily used *in vitro*, and radiotracers developed for *in vivo* PET and SPECT imaging. Several of the structural components found in gram-positive and gram-negative bacterial cell walls are not seen in humans or other pathogens, representing a strong foundation for bacteria-specific imaging. Patient-compatible tracers based on this premise will join a complement of innovative imaging methods bound for clinical use. In the field of bacteria-specific imaging, the diversity of approaches considered represents a major strength moving forward, with the potential to benefit many acutely ill patients.

Funding sources:

Grant sponsors NIH R01EB024014, NIH R01EB025985, DOD A132172. UCSF Resource Allocation Program.

Bibliography:

- (1). Treglia G Diagnostic Performance of 18F-FDG PET/CT in Infectious and Inflammatory Diseases according to Published Meta-Analyses. *Contrast Media Mol. Imaging* 2019, 2019, 3018349 DOI: 10.1155/2019/3018349. [PubMed: 31427907]
- (2). Vaidyanathan S; Patel CN; Scarsbrook AF; Chowdhury FU FDG PET/CT in infection and inflammation--current and emerging clinical applications. *Clin Radiol* 2015, 70, 787–800 DOI: 10.1016/j.crad.2015.03.010. [PubMed: 25917543]
- (3). Magnuson JE; Brown ML; Hauser MF; Berquist TH; Fitzgerald RH; Klee GG In-111-labeled leukocyte scintigraphy in suspected orthopedic prosthesis infection: comparison with other imaging modalities. *Radiology* 1988, 168, 235–239 DOI: 10.1148/radiology.168.1.3380966. [PubMed: 3380966]
- (4). Bar-Shalom R; Yefremov N; Guralnik L; Keidar Z; Engel A; Nitecki S; Israel O SPECT/CT using 67Ga and 111In-labeled leukocyte scintigraphy for diagnosis of infection. *J. Nucl. Med* 2006, 47, 587–594. [PubMed: 16595491]
- (5). Erba PA; Leo G; Sollini M; Tascini C; Boni R; Berchiolli RN; Menichetti F; Ferrari M; Lazzeri E; Mariani G Radiolabelled leucocyte scintigraphy versus conventional radiological imaging for the management of late, low-grade vascular prosthesis infections. *Eur. J. Nucl. Med. Mol. Imaging* 2014, 41, 357–368 DOI: 10.1007/s00259-013-2582-9. [PubMed: 24142027]
- (6). Kumar V; Boddeti DK (68)Ga-radiopharmaceuticals for PET imaging of infection and inflammation. *Recent Results Cancer Res* 2013, 194, 189–219 DOI: 10.1007/978-3-642-27994-2_11. [PubMed: 22918761]
- (7). Weinstein EA; Ordonez AA; DeMarco VP; Murawski AM; Pokkali S; MacDonald EM; Klunk M; Mease RC; Pomper MG; Jain SK Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxyisotriton positron emission tomography. *Sci Transl Med* 2014, 6, 259ra146 DOI: 10.1126/scitranslmed.3009815.
- (8). Mutch CA; Ordonez AA; Qin H; Parker M; Bambarger LE; Villanueva-Meyer JE; Blecha J; Carroll V; Taglang C; Flavell R; et al. [11C]Para-Aminobenzoic Acid: A Positron Emission

Tomography Tracer Targeting Bacteria-Specific Metabolism. *ACS Infect. Dis* 2018, 4, 1067–1072 DOI: 10.1021/acsinfecdis.8b00061. [PubMed: 29712422]

- (9). Zhang Z; Ordonez AA; Wang H; Li Y; Gogarty KR; Weinstein EA; Daryae F; Merino J; Yoon GE; Kalinda AS; et al. Positron Emission Tomography Imaging with 2-[18F]F- p-Aminobenzoic Acid Detects Staphylococcus aureus Infections and Monitors Drug Response. *ACS Infect. Dis* 2018, 4, 1635–1644 DOI: 10.1021/acsinfecdis.8b00182. [PubMed: 30067329]
- (10). Sellmyer MA; Lee I; Hou C; Weng C-C; Li S; Lieberman BP; Zeng C; Mankoff DA; Mach RH Bacterial infection imaging with [18F]fluoropropyl-trimethoprim. *Proc. Natl. Acad. Sci. USA* 2017, 114, 8372–8377 DOI: 10.1073/pnas.1703109114. [PubMed: 28716936]
- (11). Gilbert JA; Blaser MJ; Caporaso JG; Jansson JK; Lynch SV; Knight R Current understanding of the human microbiome. *Nat. Med* 2018, 24, 392–400 DOI: 10.1038/nm.4517. [PubMed: 29634682]
- (12). Wright EK; Kamm MA; Teo SM; Inouye M; Wagner J; Kirkwood CD Recent advances in characterizing the gastrointestinal microbiome in Crohn’s disease: a systematic review. *Inflamm. Bowel Dis* 2015, 21, 1219–1228 DOI: 10.1097/MIB.0000000000000382. [PubMed: 25844959]
- (13). Mahdavinia M; Keshavarzian A; Tobin MC; Landay AL; Schleimer RP A comprehensive review of the nasal microbiome in chronic rhinosinusitis (CRS). *Clin. Exp. Allergy* 2016, 46, 21–41 DOI: 10.1111/cea.12666. [PubMed: 26510171]
- (14). Haldar K; Bafadhel M; Lau K; Berg A; Kwambana B; Keadze T; Ramsheh MY; Barker B; Haldar P; Johnston S; et al. Microbiome balance in sputum determined by PCR stratifies COPD exacerbations and shows potential for selective use of antibiotics. *PLoS One* 2017, 12, e0182833 DOI: 10.1371/journal.pone.0182833. [PubMed: 28841671]
- (15). Dumont RA; Keen NN; Bloomer CW; Schwartz BS; Talbott J; Clark AJ; Wilson DM; Chin CT Clinical Utility of Diffusion-Weighted Imaging in Spinal Infections. *Clin Neuroradiol* 2018, 1–8 DOI: 10.1007/s00062-018-0681-5. [PubMed: 29417154]
- (16). Talbott JF; Shah VN; Uzelac A; Narvid J; Dumont RA; Chin CT; Wilson DM Imaging-Based Approach to Extradural Infections of the Spine. *Semin Ultrasound CT MR* 2018, 39, 570–586 DOI: 10.1053/j.sult.2018.09.003. [PubMed: 30527522]
- (17). Zimmer V; Lammert F Acute Bacterial Cholangitis. *Viszeralmedizin* 2015, 31, 166–172 DOI: 10.1159/000430965. [PubMed: 26468310]
- (18). Aghdassi AA; Mayerle J; Kraft M; Sielenkämper AW; Heidecke C-D; Lerch MM Pancreatic pseudocysts--when and how to treat? *HPB (Oxford)* 2006, 8, 432–441 DOI: 10.1080/13651820600748012. [PubMed: 18333098]
- (19). Sanverdi SE; Ergen BF; Oznur A Current challenges in imaging of the diabetic foot. *Diabet. Foot Ankle* 2012, 3 DOI: 10.3402/dfa.v3i0.18754.
- (20). Bhagirath AY; Li Y; Somayajula D; Dadashi M; Badr S; Duan K Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. *BMC Pulm Med* 2016, 16, 174 DOI: 10.1186/s12890-016-0339-5. [PubMed: 27919253]
- (21). Weiner RE The mechanism of 67Ga localization in malignant disease. *Nucl Med Biol* 1996, 23, 745–751 DOI: 10.1016/0969-8051(96)00119-9. [PubMed: 8940716]
- (22). Goldsmith SJ; Vallabhajosula S Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applications. *Semin Nucl Med* 2009, 39, 2–10 DOI: 10.1053/j.semnuclmed.2008.08.002. [PubMed: 19038596]
- (23). Slough C; Masters SC; Hurley RA; Taber KH Clinical positron emission tomography (PET) neuroimaging: advantages and limitations as a diagnostic tool. *J. Neuropsychiatry Clin. Neurosci* 2016, 28, A4, 67–71 DOI: 10.1176/appi.neuropsych.16030044.
- (24). Raji CA; Tarzwell R; Pavel D; Schneider H; Uszler M; Thornton J; van Lierop M; Cohen P; Amen DG; Henderson T Clinical utility of SPECT neuroimaging in the diagnosis and treatment of traumatic brain injury: a systematic review. *PLoS One* 2014, 9, e91088 DOI: 10.1371/journal.pone.0091088. [PubMed: 24646878]
- (25). Assessment of brain SPECT. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 1996, 46, 278–285. [PubMed: 8559404]

- (26). Ullah MN; Pratiwi E; Cheon J; Choi H; Yeom JY Instrumentation for Time-of-Flight Positron Emission Tomography. *Nucl. Med. Mol. Imaging* 2016, 50, 112–122 DOI: 10.1007/s13139-016-0401-5. [PubMed: 27275359]
- (27). Neumann K; Flavell R; Wilson DM Exploring metabolism in vivo using endogenous ¹¹C metabolic tracers. *Semin Nucl Med* 2017, 47, 461–473 DOI: 10.1053/j.semnuclmed.2017.05.003. [PubMed: 28826521]
- (28). Ning X; Lee S; Wang Z; Kim D; Stubblefield B; Gilbert E; Murthy N Maltodextrin-based imaging probes detect bacteria in vivo with high sensitivity and specificity. *Nat. Mater* 2011, 10, 602–607 DOI: 10.1038/nmat3074. [PubMed: 21765397]
- (29). Ning X; Seo W; Lee S; Takemiya K; Rafi M; Feng X; Weiss D; Wang X; Williams L; Camp VM; et al. PET imaging of bacterial infections with fluorine-18-labeled maltohexaose. *Angew. Chem. Int. Ed. Engl* 2014, 53, 14096–14101 DOI: 10.1002/anie.201408533. [PubMed: 25330976]
- (30). Kuru E; Hughes HV; Brown PJ; Hall E; Tekkam S; Cava F; de Pedro MA; Brun YV; VanNieuwenhze MS In Situ probing of newly synthesized peptidoglycan in live bacteria with fluorescent D-amino acids. *Angew. Chem. Int. Ed. Engl* 2012, 51, 12519–12523 DOI: 10.1002/anie.201206749. [PubMed: 23055266]
- (31). Neumann KD; Villanueva-Meyer JE; Mutch CA; Flavell RR; Blecha JE; Kwak T; Sriram R; VanBrocklin HF; Rosenberg OS; Ohliger MA; et al. Imaging Active Infection in vivo Using D-Amino Acid Derived PET Radiotracers. *Sci. Rep* 2017, 7, 7903 DOI: 10.1038/s41598-017-08415-x. [PubMed: 28801560]
- (32). Stewart MN; Parker MFL; Jivan S; Luu JM; Huynh TL; Schulte B; Seo Y; Blecha JE; Villanueva-Meyer JE; Flavell RR; et al. High Enantiomeric Excess In-Loop Synthesis of d-[methyl-¹¹C]Methionine for Use as a Diagnostic Positron Emission Tomography Radiotracer in Bacterial Infection. *ACS Infect. Dis* 2019 DOI: 10.1021/acsinfecdis.9b00196.
- (33). Parker MFL; Luu JM; Schulte B; Huynh TL; Stewart MN; Sriram R; Yu MA; Jivan S; Turnbaugh PJ; Flavell RR; et al. Sensing Living Bacteria in Vivo Using d-Alanine-Derived ¹¹C Radiotracers. *ACS Cent. Sci* 2020 DOI: 10.1021/acscentsci.9b00743.
- (34). Fura JM; Kearns D; Pires MM D-Amino Acid Probes for Penicillin Binding Protein-based Bacterial Surface Labeling. *J. Biol. Chem* 2015, 290, 30540–30550 DOI: 10.1074/jbc.M115.683342. [PubMed: 26499795]
- (35). Thirumurugan P; Matosiuk D; Jozwiak K Click chemistry for drug development and diverse chemical-biology applications. *Chem. Rev* 2013, 113, 4905–4979 DOI: 10.1021/cr200409f. [PubMed: 23531040]
- (36). Siegrist MS; Whiteside S; Jewett JC; Aditham A; Cava F; Bertozzi CR (D)-Amino acid chemical reporters reveal peptidoglycan dynamics of an intracellular pathogen. *ACS Chem. Biol* 2013, 8, 500–505 DOI: 10.1021/cb3004995. [PubMed: 23240806]
- (37). MacKenzie DA; Sherratt AR; Chigrinova M; Kell AJ; Pezacki JP Bioorthogonal labelling of living bacteria using unnatural amino acids containing nitrones and a nitron derivative of vancomycin. *Chem. Commun. (Camb)* 2015, 51, 12501–12504 DOI: 10.1039/c5cc04901f. [PubMed: 26151942]
- (38). Dumont A; Malleron A; Awwad M; Dukan S; Vauzeilles B Click-mediated labeling of bacterial membranes through metabolic modification of the lipopolysaccharide inner core. *Angew. Chem. Int. Ed. Engl* 2012, 51, 3143–3146 DOI: 10.1002/anie.201108127. [PubMed: 22323101]
- (39). Hou S; Choi J-S; Garcia MA; Xing Y; Chen K-J; Chen Y-M; Jiang ZK; Ro T; Wu L; Stout DB; et al. Pretargeted Positron Emission Tomography Imaging That Employs Supramolecular Nanoparticles with in Vivo Bioorthogonal Chemistry. *ACS Nano* 2016, 10, 1417–1424 DOI: 10.1021/acsnano.5b06860. [PubMed: 26731174]
- (40). Pretze M; Pietzsch D; Mamat C Recent trends in bioorthogonal click-radiolabeling reactions using fluorine-18. *Molecules* 2013, 18, 8618–8665 DOI: 10.3390/molecules18078618. [PubMed: 23881051]
- (41). Billaud EMF; Belderbos S; Cleeren F; Maes W; Van de Wouwer M; Koole M; Verbruggen A; Himmelreich U; Geukens N; Bormans G Pretargeted PET Imaging Using a Bioorthogonal ¹⁸F-Labeled trans-Cyclooctene in an Ovarian Carcinoma Model. *Bioconj Chem* 2017, 28, 2915–2920 DOI: 10.1021/acs.bioconjchem.7b00635. [PubMed: 29191024]

- (42). Peplow M Click chemistry targets antibody-drug conjugates for the clinic. *Nat. Biotechnol* 2019 DOI: 10.1038/d41587-019-00017-4.
- (43). Kim E; Koo H Biomedical applications of copper-free click chemistry: in vitro, in vivo, and ex vivo. *Chem. Sci* 2019, 10, 7835–7851 DOI: 10.1039/c9sc03368h. [PubMed: 31762967]
- (44). Zhao G; Meier TI; Kahl SD; Gee KR; Blaszcak LC BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins. *Antimicrob. Agents Chemother* 1999, 43, 1124–1128. [PubMed: 10223924]
- (45). Tiyantong K; Doan T; Lazarus MB; Fang X; Rudner DZ; Walker S Imaging peptidoglycan biosynthesis in *Bacillus subtilis* with fluorescent antibiotics. *Proc. Natl. Acad. Sci. USA* 2006, 103, 11033–11038 DOI: 10.1073/pnas.0600829103. [PubMed: 16832063]
- (46). Daniel RA; Errington J Control of cell morphogenesis in bacteria: two distinct ways to make a rod-shaped cell. *Cell* 2003, 113, 767–776 DOI: 10.1016/s0092-8674(03)00421-5. [PubMed: 12809607]
- (47). Newton BA A fluorescent derivative of polymyxin: its preparation and use in studying the site of action of the antibiotic. *J. Gen. Microbiol* 1955, 12, 226–236 DOI: 10.1099/00221287-12-2-226. [PubMed: 14367746]
- (48). Jalilian AR; Hosseini MA; Majdabadi... , A. Evaluation of [201 Tl](III) Vancomycin in normal rats. *Nuclear Medicine ...* 2008.
- (49). Stone MRL; Butler MS; Phetsang W; Cooper MA; Blaskovich MAT Fluorescent antibiotics: new research tools to fight antibiotic resistance. *Trends Biotechnol* 2018, 36, 523–536 DOI: 10.1016/j.tibtech.2018.01.004. [PubMed: 29478675]
- (50). Mills B; Bradley M; Dhaliwal K Optical imaging of bacterial infections. *Clin. Transl. Imaging* 2016, 4, 163–174 DOI: 10.1007/s40336-016-0180-0. [PubMed: 27340649]
- (51). Gambhir SS Molecular imaging of cancer with positron emission tomography. *Nat. Rev. Cancer* 2002, 2, 683–693 DOI: 10.1038/nrc882. [PubMed: 12209157]
- (52). Hope TA; Aggarwal R; Chee B; Tao D; Greene KL; Cooperberg MR; Feng F; Chang A; Ryan CJ; Small EJ; et al. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. *J. Nucl. Med* 2017, 58, 1956–1961 DOI: 10.2967/jnumed.117.192476. [PubMed: 28522741]
- (53). Auletta S; Baldoni D; Varani M; Galli F; Hajar IA; Duatti A; Ferro-Flores G; Trampuz A; Signore A Comparison of 99mTc-UBI 29–41, 99mTc-ciprofloxacin, 99mTc-ciprofloxacin dithiocarbamate and 111In-biotin for targeting experimental *Staphylococcus aureus* and *Escherichia coli* foreign-body infections: an ex-vivo study. *Q. J. Nucl. Med. Mol. Imaging* 2019, 63, 37–47 DOI: 10.23736/S1824-4785.17.02975-2. [PubMed: 28849632]
- (54). Langer O; Brunner M; Zeitlinger M; Ziegler S; Müller U; Dobrozemsky G; Lackner E; Joukhadar C; Mitterhauser M; Wadsak W; et al. In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. *Eur. J. Nucl. Med. Mol. Imaging* 2005, 32, 143–150 DOI: 10.1007/s00259-004-1646-2. [PubMed: 15690222]
- (55). Ordonez AA; Wang H; Magombedze G; Ruiz-Bedoya CA; Srivastava S; Chen A; Tucker EW; Urbanowski ME; Pieterse L; Fabian Cardozo E; et al. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. *Nat. Med* 2020 DOI: 10.1038/s41591-020-0770-2.
- (56). Li J; Zheng H; Fodah RA; Warawa J; Ng CK Validation of 2-(18)F-fluorodeoxysorbitol ((18)F-FDS) as a potential radiopharmaceutical for imaging bacterial infection in the lung. *J. Nucl. Med* 2017, 59, 134–139 DOI: 10.2967/jnumed.117.195420. [PubMed: 28848037]
- (57). Yao S; Xing H; Zhu W; Wu Z; Zhang Y; Ma Y; Liu Y; Huo L; Zhu Z; Li Z; et al. Infection Imaging With (18)F-FDS and First-in-Human Evaluation. *Nucl Med Biol* 2016, 43, 206–214 DOI: 10.1016/j.nucmedbio.2015.11.008. [PubMed: 26924501]
- (58). Gowrishankar G; Namavari M; Jouannot EB; Hoehne A; Reeves R; Hardy J; Gambhir SS Investigation of 6-[18F]-fluoromaltose as a novel PET tracer for imaging bacterial infection. *PLoS One* 2014, 9, e107951 DOI: 10.1371/journal.pone.0107951. [PubMed: 25243851]
- (59). Namavari M; Gowrishankar G; Hoehne A; Jouannot E; Gambhir SS Synthesis of [18F]-labelled maltose derivatives as PET tracers for imaging bacterial infection. *Mol. Imaging Biol* 2015, 17, 168–176 DOI: 10.1007/s11307-014-0793-5. [PubMed: 25277604]

- (60). Gowrishankar G; Hardy J; Wardak M; Namavari M; Reeves RE; Neofytou E; Srinivasan A; Wu JC; Contag CH; Gambhir SS Specific Imaging of Bacterial Infection Using $6''$ -18F-Fluoromaltotriose: A Second-Generation PET Tracer Targeting the Maltodextrin Transporter in Bacteria. *J. Nucl. Med* 2017, 58, 1679–1684 DOI: 10.2967/jnumed.117.191452. [PubMed: 28490473]
- (61). Kalita M; Parker MFL; Luu JM; Stewart MN; Blecha JE; VanBrocklin HF; Evans MJ; Flavell RR; Rosenberg OS; Ohliger MA; et al. Arabinofuranose-derived positron-emission tomography radiotracers for detection of pathogenic microorganisms. *J. Labelled Comp. Radiopharm* 2020 DOI: 10.1002/jlcr.3835.
- (62). Petrik M; Umlaufova E; Raclavsky V; Palyzova A; Havlicek V; Haas H; Novy Z; Dolezal D; Hajdich M; Decristoforo C Imaging of *Pseudomonas aeruginosa* infection with Ga-68 labelled pyoverdine for positron emission tomography. *Sci. Rep* 2018, 8, 15698 DOI: 10.1038/s41598-018-33895-w. [PubMed: 30356077]
- (63). Auletta S; Varani M; Horvat R; Galli F; Signore A; Hess S PET radiopharmaceuticals for specific bacteria imaging: A systematic review. *J Clin Med* 2019, 8 DOI: 10.3390/jcm8020197.
- (64). Ordonez AA; Sellmyer MA; Gowrishankar G; Ruiz-Bedoya CA; Tucker EW; Palestro CJ; Hammoud DA; Jain SK Molecular imaging of bacterial infections: Overcoming the barriers to clinical translation. *Sci Transl Med* 2019, 11 DOI: 10.1126/scitranslmed.aax8251.
- (65). Lawal I; Zeevaart J; Ebenhan T; Ankrah A; Vorster M; Kruger HG; Govender T; Sathegke M Metabolic imaging of infection. *J. Nucl. Med* 2017, 58, 1727–1732 DOI: 10.2967/jnumed.117.191635. [PubMed: 28818989]
- (66). Boos W; Shuman H Maltose/maltodextrin system of *Escherichia coli*: transport, metabolism, and regulation. *Microbiol. Mol. Biol. Rev* 1998, 62, 204–229. [PubMed: 9529892]
- (67). Carroll VN; Truillet C; Shen B; Flavell RR; Shao X; Evans MJ; VanBrocklin HF; Scott PJH; Chin FT; Wilson DM [(11)C]Ascorbic and [(11)C]dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. *Chem. Commun. (Camb)* 2016, 52, 4888–4890 DOI: 10.1039/c6cc00895j. [PubMed: 26963495]
- (68). Bugg TD; Walsh CT Intracellular steps of bacterial cell wall peptidoglycan biosynthesis: enzymology, antibiotics, and antibiotic resistance. *Nat Prod Rep* 1992, 9, 199–215. [PubMed: 1436736]
- (69). Lam H; Oh D-C; Cava F; Takacs CN; Clardy J; de Pedro MA; Waldor MK D-amino acids govern stationary phase cell wall remodeling in bacteria. *Science* (80-.) 2009, 325, 1552–1555 DOI: 10.1126/science.1178123.
- (70). Lobanovska M; Pilla G Penicillin's discovery and antibiotic resistance: lessons for the future? *Yale J Biol Med* 2017, 90, 135–145. [PubMed: 28356901]
- (71). Kalman D; Barriere SL Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins. *Tex Heart Inst J* 1990, 17, 203–215. [PubMed: 15227172]
- (72). Levine DP Vancomycin: a history. *Clin. Infect. Dis* 2006, 42 Suppl 1, S5–12 DOI: 10.1086/491709. [PubMed: 16323120]
- (73). Wei Y; Qiu W; Zhou X-D; Zheng X; Zhang K-K; Wang S-D; Li Y-Q; Cheng L; Li J-Y; Xu X; et al. Alanine racemase is essential for the growth and interspecies competitiveness of *Streptococcus mutans*. *Int. J. Oral Sci* 2016, 8, 231–238 DOI: 10.1038/ijos.2016.34. [PubMed: 27740612]
- (74). Azam MA; Jayaram U Inhibitors of alanine racemase enzyme: a review. *J Enzyme Inhib Med Chem* 2016, 31, 517–526 DOI: 10.3109/14756366.2015.1050010. [PubMed: 26024289]
- (75). Caparrós M; Pisabarro AG; de Pedro MA Effect of D-amino acids on structure and synthesis of peptidoglycan in *Escherichia coli*. *J. Bacteriol* 1992, 174, 5549–5559 DOI: 10.1128/jb.174.17.5549-5559.1992. [PubMed: 1512190]
- (76). Hsu Y-P; Rittichier J; Kuru E; Yablonowski J; Pasciak E; Tekkam S; Hall E; Murphy B; Lee TK; Garner EC; et al. Full color palette of fluorescent d-amino acids for in situ labeling of bacterial cell walls. *Chem. Sci* 2017, 8, 6313–6321 DOI: 10.1039/c7sc01800b. [PubMed: 28989665]
- (77). Caparrós M; Arán V; de Pedro MA Incorporation of S-[3H]methyl-D-cysteine into the peptidoglycan of ether-treated cells of *Escherichia coli*. *FEMS Microbiol. Lett* 1992, 72, 139–146 DOI: 10.1016/0378-1097(92)90519-t. [PubMed: 1505738]

- (78). Yoshimura T; Esaki N Amino Acid Racemases: Functions and Mechanisms. *J. Biosci. Bioeng* 2003, 96, 103–109 DOI: 10.1263/jbb.96.103. [PubMed: 16233494]
- (79). Kawazoe T; Park HK; Iwana S; Tsuge H Human D-amino acid oxidase: an update and review. *The Chemical ...* 2007.
- (80). Liang H; DeMeester KE; Hou C-W; Parent MA; Caplan JL; Grimes CL Metabolic labelling of the carbohydrate core in bacterial peptidoglycan and its applications. *Nat Commun* 2017, 8, 15015 DOI: 10.1038/ncomms15015. [PubMed: 28425464]
- (81). Zargar V; Asghari M; Dashti A A review on chitin and chitosan polymers: structure, chemistry, solubility, derivatives, and applications. *ChemBioEng Reviews* 2015.
- (82). Salvatore S; Heuschkel R; Tomlin S; Davies SE; Edwards S; Walker-Smith JA; French I; Murch SH A pilot study of N-acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease. *Aliment. Pharmacol. Ther* 2000, 14, 1567–1579. [PubMed: 11121904]
- (83). Fujiwara T; Kubota K; Sato T; Matsuzawa T; Tada M; Iwata R; Itoh M; Hatazawa J; Sato K; Fukuda H N-[18F]fluoroacetyl-D-glucosamine: a potential agent for cancer diagnosis. *J. Nucl. Med* 1990, 31, 1654–1658. [PubMed: 2213188]
- (84). Martínez ME; Kiyono Y; Noriki S; Inai K; Mandap KS; Kobayashi M; Mori T; Tokunaga Y; Tiwari VN; Okazawa H; et al. New radiosynthesis of 2-deoxy-2-[(18F)fluoroacetamido-D-glucopyranose and its evaluation as a bacterial infections imaging agent. *Nucl Med Biol* 2011, 38, 807–817 DOI: 10.1016/j.nucmedbio.2011.02.006. [PubMed: 21757364]
- (85). Raetz CRH; Whitfield C Lipopolysaccharide endotoxins. *Annu. Rev. Biochem* 2002, 71, 635–700 DOI: 10.1146/annurev.biochem.71.110601.135414. [PubMed: 12045108]
- (86). Nilsson I; Grove K; Dovala D; Uehara T; Lapointe G; Six DA Molecular characterization and verification of azido 3,8-dideoxy-D-manno-oct-2-ulosonic acid incorporation into bacterial lipopolysaccharide. *J. Biol. Chem* 2017 DOI: 10.1074/jbc.M117.814962.
- (87). Fugier E; Dumont A; Malleron A; Poquet E; Mas Pons J; Baron A; Vauzeilles B; Dukan S Rapid and Specific Enrichment of Culturable Gram Negative Bacteria Using Non-Lethal Copper-Free Click Chemistry Coupled with Magnetic Beads Separation. *PLoS One* 2015, 10, e0127700 DOI: 10.1371/journal.pone.0127700. [PubMed: 26061695]
- (88). Brown S; Santa Maria JP; Walker S Wall teichoic acids of gram-positive bacteria. *Annu. Rev. Microbiol* 2013, 67, 313–336 DOI: 10.1146/annurev-micro-092412-155620. [PubMed: 24024634]
- (89). Swoboda JG; Campbell J; Meredith TC; Walker S Wall teichoic acid function, biosynthesis, and inhibition. *Chembiochem* 2010, 11, 35–45 DOI: 10.1002/cbic.200900557. [PubMed: 19899094]
- (90). Andre G; Deghorain M; Bron PA; van Swam II; Kleerebezem M; Hols P; Dufrene YF Fluorescence and atomic force microscopy imaging of wall teichoic acids in *Lactobacillus plantarum*. *ACS Chem. Biol* 2011, 6, 366–376 DOI: 10.1021/cb1003509. [PubMed: 21218855]
- (91). Pickett JE; Thompson JM; Sadowska A; Tkaczyk C; Sellman BR; Minola A; Corti D; Lanzavecchia A; Miller LS; Thorek DL Molecularly specific detection of bacterial lipoteichoic acid for diagnosis of prosthetic joint infection of the bone. *Bone Res* 2018, 6, 13 DOI: 10.1038/s41413-018-0014-y. [PubMed: 29707402]
- (92). Kwon H-Y; Liu X; Choi EG; Lee JY; Choi S-Y; Kim J-Y; Wang L; Park S-J; Kim B; Lee Y-A; et al. Development of universal fluorescent Gram-positive bacteria probe. *Angew. Chem. Int. Ed. Engl* 2019 DOI: 10.1002/anie.201902537.
- (93). Mason DJ; Shanmuganathan S; Mortimer FC; Gant VA A fluorescent Gram stain for flow cytometry and epifluorescence microscopy. *Appl. Environ. Microbiol* 1998, 64, 2681–2685. [PubMed: 9647848]
- (94). Cash HL; Whitham CV; Behrendt CL; Hooper LV Symbiotic bacteria direct expression of an intestinal bactericidal lectin. *Science (80-.)* 2006, 313, 1126–1130 DOI: 10.1126/science.1127119.
- (95). Alderwick LJ; Harrison J; Lloyd GS; Birch HL The Mycobacterial Cell Wall--Peptidoglycan and Arabinogalactan. *Cold Spring Harb. Perspect. Med* 2015, 5, a021113 DOI: 10.1101/cshperspect.a021113. [PubMed: 25818664]

- (96). Kamariza M; Shieh P; Bertozzi CR Imaging mycobacterial trehalose glycolipids; 2018; Vol. 598, pp. 355–369.
- (97). Rundell SR; Wagar ZL; Meints LM; Olson CD; O’Neill MK; Piligian BF; Poston AW; Hood RJ; Woodruff PJ; Swarts BM Deoxyfluoro-d-trehalose (FDTre) analogues as potential PET probes for imaging mycobacterial infection. *Org. Biomol. Chem* 2016, 14, 8598–8609 DOI: 10.1039/c6ob01734g. [PubMed: 27560008]
- (98). Wilson BR; Bogdan AR; Miyazawa M; Hashimoto K; Tsuji Y Siderophores in iron metabolism: from mechanism to therapy potential. *Trends Mol. Med* 2016, 22, 1077–1090 DOI: 10.1016/j.molmed.2016.10.005. [PubMed: 27825668]
- (99). Petrik M; Zhai C; Haas H; Decristoforo C Siderophores for molecular imaging applications. *Clin. Transl. Imaging* 2017, 5, 15–27 DOI: 10.1007/s40336-016-0211-x. [PubMed: 28138436]
- (100). Slavin YN; Asnis J; Häfeli UO; Bach H Metal nanoparticles: understanding the mechanisms behind antibacterial activity. *J. Nanobiotechnology* 2017, 15, 65 DOI: 10.1186/s12951-017-0308-z. [PubMed: 28974225]

Synopsis:

Cell-wall targeted probes, labeled for both fluorescence microscopy and nuclear imaging can improve our understanding of microbial behavior *in vitro* and *in vivo*.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





Figure 1. Maltodextrin transporter-targeted fluorescent and PET probes published from the Murthy group, highlighting the synergy between optical imaging and PET. (A) Data obtained using the MDP-2 NIR probe in a simple preclinical model of bacterial infection, in which fluorescent signal is seen in living *E. coli* but not in LPS-induced inflammation in the opposite flank (adapted from Ning et al. 2011). (B) Similar findings for the MH¹⁸F maltohexose-derived positron emission tomography tracer (adapted from Ning et al. 2014).

**Figure 2.**

Comparison of D-amino acid derived structures modified for fluorescent detection and positron emission tomography (PET) imaging, with the sites of modification marked in red. (A) Two D-amino acid structures incorporating hydroxycoumarin and nitrobenzofuran-derived fluorophores, HADA and NADA respectively (Kuru *et al.* 2012). (B) Two ^{11}C -labelled amino acids D-[α - ^{11}C]met (Neumann *et al.* 2017) and D-[3- ^{11}C]ala (Parker *et al.* 2020) with the ^{11}C nucleus highlighted in red. (C) The enantioselective radiosynthesis of D-[3- ^{11}C]ala from an achiral glycine-derived precursor via reaction with ^{11}C methyl iodide in the presence of a cinchonidinium-derived phase-transfer catalyst.




Figure 3. Use of D-amino acid derived structures to label peptidoglycan, via direct incorporation. This study employed linkers of various lengths suggesting the preference of *S. aureus* for smaller D-amino acid derived structures (adapted from Fura *et al.* 2015).




Figure 4. Bio-orthogonal chemistry developed to detect D-amino acids. (A) Chemistry developed by Siegrist et. al. used either an alkyne or azide containing side-chain with subsequent click reaction with a fluorescent moiety. (adapted from Siegrist *et al.* 2013). (B) A newer approach to bio-orthogonal chemistry using nitron and strained alkyne cycloaddition chemistry. (C) Nitron cycloadditions applied to D-alanine and D-lysine analogs (adapted from MacKenzie et al. 2015).




Figure 5.

Vancomycin-derived conjugates used for single photon emission computed tomography (SPECT) and fluorescence imaging. (A) Modified ²⁰¹Tl-containing derivative of vancomycin (Jalilian *et al.* 2008) (C) A commercially available BODIPY functionalized vancomycin.




Figure 6.

Targeted cell wall structures in fluorescent and SPECT/PET Probe development (. (A) Basic structures of gram-negative and gram-positive cell walls highlighting the location of peptidoglycan, lipopolysaccharide, teichoic acids, and transporters (adapted from Slavin *et al.* 2017)¹⁰⁰ (B) Structure of the peptidoglycan monomer; both muropeptide D-amino acids and N-acetyl muramic acid from the sugar backbone have been targeted for detection.




Figure 7. Use of bio-orthogonal chemistry to detect peptidoglycan incorporation of N-acetyl muramic acid (adapted from Liang et al. 2017). (A) The chemical structure of native peptidoglycan, with bioorthogonal modified peptidoglycan and site(s) of fluorescent labelling indicated. (B) Structures of N-acetyl muramic acid monomer and its functionalized derivatives.




Figure 8.

Use of bio-orthogonal chemistry to detect incorporation of 3-deoxy-D-manno-octulosonic acid (KDO) in gram-negative bacteria (adapted from Dumont *et al.* 2012). (A) The chemical structure of lipopolysaccharide with KDO content highlighted, with biorthogonal modified peptidoglycan and site(s) of fluorescent labelling indicated. (B) Structures of modified KDO (KDO-N₃) and alkyne-bearing fluorescent dye used (C) Fluorescent microscopy showing detection of bacteria using KDO-N₃ with magnified view showing localization of signal to the membrane.

Table 1.

Comparison between optical imaging and radionuclide-based PET and SPECT imaging.

	OPTICAL	PET/SPECT
<i>In vitro</i> analysis	Yes	Yes
<i>In vivo</i> analysis	Yes	Yes
Penetrating depth	~cm	Full body
Activatable	Yes	No
Detected component	Fluorophore	Radionuclide
Detection method	Photons	Positrons/Gamma rays
Concentration	nM	fM-pM
Instrumentation	Smaller, more portable	Larger, PET/CT or PET/MR

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript